Pamidronate Administration in Breast Cancer Patients With Bone Metastases
Status:
Completed
Trial end date:
2004-06-04
Target enrollment:
Participant gender:
Summary
The study objective is to evaluate the differences, in terms of first occurrence of a
skeletal event, in patients with breast cancer and symptomatic bone metastases, when
pamidronate is administered during 2 years, or when it is administered during 6 months,
followed by a six month rest period, and again a 6 month treatment period.